达沙替尼治疗伊马替尼耐药的BCR/ABL阳性白血病  

Dasatinib in treatment of imatinib-resistant BCR / ABL positive leukemia

作　　者：严红[1] 赵海军[1] 

机构地区：[1]安徽医科大学附属安庆医院血液科,安徽安庆246003

出　　处：《安徽医药》2014年第5期946-948,共3页Anhui Medical and Pharmaceutical Journal

摘　　要：目的评价达沙替尼治疗伊马替尼耐药的BCR/ABL阳性白血病的疗效和安全性。方法对9例伊马替尼耐药的慢性髓系白血病（CML）或Ph阳性急性淋巴细胞白血病（Ph＋ALL）患者,给予达沙替尼100～140 mg·d-1口服治疗,评估疗效和耐受情况。结果 9例伊马替尼耐药的BCR/ABL阳性白血病,2例CML-CP患者均获得CHR,1例达CCyR；5例CML-BC患者中4例获得CHR和PCyR,1例NR；2例Ph＋ALL患者中1例检测到E255V突变,采用达沙替尼治疗达CHR和PCyR,1例诱导缓解时,同时行VDP方案化疗,继发严重感染死亡。结论达沙替尼治疗伊马替尼耐药的BCR/ABL阳性白血病患者可获得血液学甚至细胞遗传学缓解,且耐受性好。This study was aimed to evaluate the efficacy and safety of dasatinib in BCR /ABL positive leukemia patients with resistance to imatinib. Method 9 patients with imatinib-resistant chronic myelogenous leukemia（ CML） or Philadelphia chromosome positive acute lymphocytic leukemia（ Ph＋ALL） received 100 ～ 140 mg·d-1dasatinib orally. Their overall survival and tolerance were evaluated. Results After the dasatinib treatment,2 patients with CML in chronic phase achieved complete hematologic response（ CHR）,one of them achieved complete cytogenetic response（ CCyR）;4 of 5 patients with CML in blast crisis achieved CHR and partly cytogenetic response（ PCyR）;one patient had no response. Treated with dasatinib,one patient with Ph＋ALL,presented with E255V mutation,achieved CHR and PCyR. The other died of infection. Conlusion Receiving therapy of dasatinib,patients with resistance to imatinib could achieve CHR,even PCyR.

关 键 词：达沙替尼 伊马替尼 白血病 

分 类 号：R733.7[医药卫生—肿瘤]